Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults.
Latest Information Update: 06 Feb 2014
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype; Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
- 15 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
- 16 Mar 2010 Planned end date changed from 1 Apr 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 15 Jun 2007 New trial record.